Dr. Scarlett said at the conference that Gern is looking to diversify and buy another company or promising drug.
With the stock trading under $5.00 and with only 170 Million in Cash such action seems premature and
could limit any upward movement in the stock price. Not a good move in my opinion.
I don't think there are any reports that JNJ has sought accelerated approval. Just a request for such approval would probably move the share price and be reportable news.
I received a message from TD Ameritrade yesterday and they verified that the $369.91 (cost) for the 1541 shares due to the spinoff of the shares GERN to AST is correct. That works out to a cost basis of only .24 cents a share.
Received the following from TD Ameritrade: "We have received your inquiry regarding your account. Per your request we have reviewed and verified that AST is reflecting correctly in your account with a cost of $369.91 for 1541 shares due to the spinoff of the shares GERN to AST". That works out to about .24 cents per share (cost).
Thank you for the reply. Based on what TD Ameritrade is posting my cost is around .24 cents a share. I will have to find some source detailing this transaction. Thanks again.
I received 1541 shares of AST on the spinoff and TD Ameritrade is showing a total cost of $369.81. Is that the amount being reflected on other brokers account. Appreciate any comments.
Normally, a short squeeze covers a number of days. If there are 30 Million shares shorted as mentioned I suspect the shorts will cover over a period of 4-5 days. The covering of 30 million shares would not take place all at once.
The only drug Gern presently has is Imet and J & J has exclusive rights to drug with a maximum cost (if everything goes right) of under 1 Billion dollars. See no reason why J & J would purchase gern or any other company would be interested because of this agreement. Maybe way down the line when and if a drug gets to market J & J may then take a look and see if it is better to maintain exclusive rights and pay the royalties or outright purchase. But the speculation of a purchase now does not seem to fit the circumstances.
Yahoo's shares do not come out of lock up until September, so the 400 million plus coming out of lockup in March does not represent any of Yahoo's shares.